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Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography 
predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome 
in chronic kidney disease patients.
Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean 
age, 57.5 years).
Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9%) patients with metabolic syndrome, 
diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine 
albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein 
levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P 
< 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 
0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum 
albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = -0.881, 
P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased 
metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009-1.183; P = 0.029) 
even after adjusting for multiple confounding factors.
Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict 
increased metabolic syndrome risk in chronic kidney disease patients.
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Introduction
Metabolic syndrome (MS), comprising hypertension, 
hypertriglyceridemia, hyperglycemia, low high-density 
lipoprotein cholesterol (HDL-C) levels, and central obe-
sity, is closely correlated with insulin resistance, chronic 
inflammation, and cardiovascular disease development 
[1]. Several studies reported that MS is associated with 
chronic kidney disease (CKD) or albuminuria [2,3], and 
that patients with MS have increased all-cause and car-
diovascular mortality in both CKD and the general popu-
lations [4]. Regarding the relationship between MS and 
CKD, several epidemiologic studies demonstrate that 
hyperglycemia, hypertension, low HDL-C levels, and hy-
pertriglyceridemia were major risk factors for CKD devel-
opment and progression. However, waist circumference, 
body mass index (BMI), and obesity, important signs of 
insulin resistance of MS, are confusing factors, especially 
in CKD patients.
Obese populations with renal impairment showed 
reverse epidemiology compared with the general popu-
lation [5]. This paradox is not explained by traditional 
pathophysiologic mechanisms; thus, investigation of 
factors such as sarcopenic obesity [6], waist-to-hip ratio 
[7], or metabolically healthy obesity [8] is needed. Among 
these surrogate findings of metabolic derangements, 
interest in the liver as a phenotype of sarcopenia and 
central obesity has been increasing in the last decade 
[9]. Recent observations suggest that fatty liver or ste-
atohepatitis, are a surrogate marker for MS. In addition, 
non-alcoholic fatty liver disease (NAFLD) is an extremely 
common liver disease accompanied by metabolic de-
rangements and is considered a hepatic manifestations 
of MS [10]. NAFLD is strongly associated with insulin re-
sistance caused by low physical activity and increased fat 
mass [11].
Transient elastography (FibroScan; Echosens, Paris, 
France) was originally invented for non-invasive detec-
tion and assessing liver cirrhosis severity [12]. Transient 
elastography has recently been used for evaluating liver 
elasticity and viscosity with ultrasonic signals, known as 
the controlled attenuation parameter (CAP). Accumulat-
ing evidences suggest that CAP could estimate the degree 
of hepatic steatosis and be a substitute for invasive liver 
biopsies [13]. Moreover, previous studies showed that CAP 
is useful in assessing the severity of NAFLD and is closely 
associated with MS in the general populations [14].
Therefore, this study aimed to elucidate whether CAP 
measurement using transient elastography has a predic-
tive role in assessing metabolic derangements in CKD 
patients.
Methods
Ethics statement
The study was carried out in accordance with the Dec-
laration of Helsinki and approved by the Institutional 
Review Board of Yonsei University Health System (YUHS) 
Clinical Trial Center.
Subjects
All pre-dialysis CKD patients without liver disease who 
underwent transient elastography at YUHS were initially 
screened for enrollment between November 2011 and 
December 2014 in this observational study. Patients un-
der 18 years old were excluded. The exclusion criteria 
included the presence of hepatitis B surface antigen, 
hepatitis C virus antibodies, concomitant or previous 
history of liver cirrhosis, alcoholic hepatitis, alcoholic 
liver disease, drug induced hepatitis, fulminant hepatitis, 
autoimmune hepatitis, primary biliary cirrhosis, primary 
sclerosing cholangitis, hepatocellular carcinoma, biliary 
tract cancer, gallbladder cancer, any cancer with metas-
tasis to the liver, or type 1 hepatorenal syndrome. Patients 
whose MS parameters were unavailable were also ex-
cluded. Finally, 465 CKD patients were analyzed (Fig. 1).
Clinical and biochemical data collection
Demographic and clinical data were collected from 
the registered database at YUHS. BMI was calculated 
as weight divided by square of height (kg/m2). Diabe-
tes mellitus and hypertension were defined as previous 
described [15,16]. CKD stage was defined by the Kidney 
Disease Improving Global Outcomes 2012 guideline 
[17], and estimated glomerular filtration rate (eGFR) was 
calculated by the CKD epidemiology collaboration equa-
tion [18]. Biochemical data including urine albumin-to-
creatinine ratio (UACR) was analyzed before or after 6 
months at the time of transient elastography. Serum total 
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cholesterol, HDL-C, low-density lipoprotein cholesterol, 
and triglyceride levels were measured by enzymatic colo-
rimetry using an autoanalyzer (Hitachi 7150; Hitachi Ltd, 
Tokyo, Japan), and high-sensitivity C-reactive protein 
(hs-CRP) levels were determined by a latex-enhanced 
immunonephelometric method using a BNII analyzer 
(Dade Behring, Newark, DE, USA).
Diagnosis of metabolic syndrome
The National Cholesterol Education Program (Adult 
Treatment Panel [ATP] III) [19] bases the diagnosis of MS 
on the presence of three or more of the following: 1) sys-
tolic blood pressure ≥ 130 mmHg and/or diastolic blood 
pressure ≥ 85 mmHg; 2) triglyceride levels ≥ 150 mg/
dL, 3) HDL-C levels < 40 mg/dL in men or < 50 mg/dL in 
women; 4) fasting plasma glucose levels ≥ 110 mg/dL; 
and 5) abdominal obesity. We based abdominal obesity 
on BMI rather than on waist circumference because of 
the participants with a BMI ≥ 25 kg/m2 classified centrally 
obese in accordance with the Western Pacific Region of 
the World Health Organization (WPRO) criteria [20]. The 
modified ATP III definition used in this study has been 
determined to be more accurate than the WPRO criteria 
for the diagnosis of MS in Asians [21].
Liver stiffness and controlled attenuation parameter 
measurements
Liver stiffness (LS) and CAP measurements were per-
formed by transient elastography on the right lobe of the 
liver through the intercostal spaces while patients were 
lying in the dorsal decubitus position with the right arm 
in maximal abduction. The final LS result was expressed 
in kPa and was the median value of 10 measurements 
performed between 25 and 65 mm depth. Only result 
with 10 valid shots and an interquartile range divided by 
median LS ratio < 30% were included [12].
The principle of CAP measurement has been described 
previously [22]. In brief, the CAP measures reflected ul-
trasonic attenuations at 3.5 MHz using signals acquired 
by transient elastography. The final CAP was computed 
only when the associated LS measurement was valid and 
using the same signals as the one used to measure LS. 
Therefore, both LS and CAP were obtained simultane-
ously and in the same volume of liver parenchyma. The 
final CAP value was presented by the median of individu-
al CAP values and was expressed in dB/m [14].
Statistical analysis
Continuous variables were expressed as mean ± stan-
dard deviation or median (range), while categorical vari-
ables were expressed as a number (percentage). Normal-
ity of distribution was ascertained with the Kolmogorov-
Smirnov test. To compare differences between patients 
with and without MS, Student’s t-test or the Mann-
Whitney U-test were used for continuous variables, and 
the chi-square test or the Fisher’s exact test were used 
for categorical variables. Univariate and multiple linear 
regression analyses were performed to determine signifi-
cant factors associated with LS and CAP. Regarding vari-
able distribution, UACR, hs-CRP, and LS were used with 
natural log values for linear regression analysis. The vari-
ables with P-values < 0.05 with univariate linear regres-
sion analysis were included in multiple linear regression 
analysis. The independent predictive role of CAP for the 
presence of MS was confirmed through logistic regres-
465 patients were eligible for the study
3,771 patients were excluded
- Age < 18 yr ( = 5)
- History of alcohol ingestion ( = 396)
- Non-CKD ( = 3,331)
- Laboratory parameters within 2 weeks from transient
elastography unavailable ( = 39)
- IQR/M of LS ratio > 30% ( = 9)
n
n
n
n
n
4,236 patients without liver disease who
underwent transient elastography were screened
Figure 1. Flow diagram of the study. 
CKD, chronic kidney disease; IQR, in-
terquartile range; LS, liver stiffness; M, 
median.
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sion analysis, which included significant variables when 
comparing baseline characteristics according to the pres-
ence of MS and multiple linear regression analysis. We 
further modified the above logistic regression analyses 
by using a restricted cubic spline model to illustrate sys-
temic relations between the degree of CAP values and the 
risk of MS. The statistical significance of the mean CAP 
across the number of MS components was verified with 
the Trend test. Statistical analysis was performed with 
IBM SPSS software for Windows version 23.0 (IBM Cor-
poration, Armonk, NY, USA). P-values < 0.05 were con-
sidered significant.
Results
Baseline characteristics according to the presence of 
metabolic syndrome
The baseline characteristics are shown in Table 1. The 
mean age of the study population was 57.5 ± 17.0 years, 
and 225 (48.4%) patients were men. There were 265 
(57.0%), 131 (28.2%), 43 (9.2%), 16 (3.4%), and 10 (2.2%) 
Table 1. Baseline characteristics of subjects
Variable Total (n = 465) Non-MS (n = 270, 58.1%) MS (n = 195, 41.9%) P
CAP (dB/m) 239 (202-274) 226 (196-259) 248 (210-302) < 0.001*
Liver stiffness (kPa) 5.3 (4.3-7.6) 4.9 (4.1-7.1) 5.6 (4.6-8.6) 0.003*
Age (yr) 57.5 ± 17.0 56.1 ± 17.9 59.5 ± 15.4 0.036
Male 225 (48.4) 119 (44.1) 106 (54.4) 0.029
BMI (kg/m2) 23.8 ± 3.5 22.8 ± 3.1 25.2 ± 3.5 < 0.001
SBP (mmHg) 128.5 ± 20.2 122.6 ± 18.6 136.6 ± 19.6 < 0.001
DBP (mmHg) 76.6 ± 12.6 73.4 ± 11.5 81.0 ± 12.8 < 0.001
CKD stage 0.008
   Stage 1 265 (57.0) 169 (62.6) 96 (49.2)
   Stage 2 131 (28.2) 70 (25.9) 61 (31.3)
   Stage 3 43 (9.2) 23 (8.5) 20 (10.3)
   Stage 4 16 (3.4) 6 (2.2) 10 (5.1)
   Stage 5 10 (2.2) 2 (0.7) 8 (4.1)
Diabetes mellitus 176 (37.8) 71 (26.3) 105 (53.8) < 0.001
Hypertension 245 (52.7) 120 (44.4) 125 (64.1) < 0.001
Fasting glucose (mg/dL) 118.9 ± 44.0 107.2 ± 35.3 135.2 ± 49.5 < 0.001
Cholesterol (mg/dL) 167.5 ± 48.3 168.5 ± 48.2 166.2 ± 48.6 0.617
Triglyceride (mg/dL) 107 (77-155) 89 (66-119) 155 (103-204) < 0.001*
HDL-C (mg/dL) 45.0 ± 13.5 49.4 ± 13.5 38.2 ± 10.4 < 0.001
LDL-C (mg/dL) 102.7 ± 42.7 104.4 ± 45.0 100.5 ± 39.4 0.365
BUN (mg/dL) 16.4 ± 9.1 15.3 ± 7.7 18.0 ± 10.6 0.003
Creatinine (mg/dL) 1.12 ± 0.93 1.00 ± 0.55 1.28 ± 1.26 0.004
eGFR (mL/min/1.73 m2) 87.9 ± 28.3 91.9 ± 26.5 82.4 ± 29.8 < 0.001
UACR (mg/g Cr) 113 (23-559) 56 (16-408) 184 (38-706) 0.003*
Serum albumin (g/dL) 3.9 ± 0.7 3.9 ± 0.7 3.7 ± 0.7 0.011
AST (U/L) 25 (19-40) 24 (18-37) 27 (20-43) 0.039*
ALT (U/L) 23 (15-42) 21 (13-36) 25 (16-53) 0.002*
Total bilirubin (mg/dL) 0.6 (0.5-0.8) 0.6 (0.5-0.9) 0.6 (0.4-0.8) 0.013*
hs-CRP (mg/L) 2.7 (0.9-17.7) 1.7 (0.6-9.9) 5.4 (1.4-28.2) < 0.001*
Data are presented as median (range), number (%), or mean ± standard deviation.
ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CAP, controlled attenuation parameter; CKD, 
chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high 
sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MS, metabolic syndrome; SBP, systolic blood pressure; UACR, urine albumin-to-
creatinine ratio. 
*Mann-Whitney’s U-test.
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patients with stage 1 to 5 CKD, respectively. The mean 
eGFR was 87.9 ± 28.3 mL/min/1.73 m2, and the median 
CAP was 239 dB/m. MS was present in 195 (41.9%) pa-
tients. Patients were divided into two groups according 
to the presence of MS. MS group had more diabetes mel-
litus (105 [53.8%] vs. 71 [26.3%], P < 0.001), significantly 
higher UACR (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 
0.003), hs-CRP levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/
L, P < 0.001), LS (5.6 [4.6-8.6] vs. 4.9 [4.1-7.1] kPa, P = 
0.003), and CAP (248 [210-302] vs. 226 [196-259] dB/m, 
P < 0.001) compared with non-MS group.
Linear regression analyses performed with liver stiffness 
or controlled attenuation parameter
Univariate linear regression analysis was performed 
to investigate the association between clinical and bio-
chemical variables with the value measured with tran-
sient elastography (Table 2). Fasting glucose, serum 
creatinine, log UACR, aspartate aminotransferase (AST), 
alanine transaminase (ALT), total bilirubin, and log hs-
CRP levels were positively correlated with log LS, while 
cholesterol, HDL-C, and serum albumin levels were neg-
atively correlated with log LS. BMI, diastolic blood pres-
sure, the presence of diabetes mellitus, fasting glucose, 
cholesterol, log triglyceride, eGFR, serum albumin, and 
ALT levels were positively correlated with CAP, while age, 
BUM, and total bilirubin levels were negatively correlated 
with CAP values.
Multiple linear regression analysis was also performed 
to clarify the independent demographic and biochemi-
cal variables with LS or CAP values in patients with CKD 
(Table 3). The analysis revealed that log LS was indepen-
dently associated with log UACR (β = 0.063, P = 0.026) and 
total bilirubin levels (β = 0.309, P < 0.001), while CAP was 
independently associated with BMI (β = 0.742, P < 0.001), 
Table 2. Univariate linear regression analyses for the association of liver stiffness and controlled attenuation parameter with vari-
ables
Variable
Liver stiffness* Controlled attenuation parameter†
β (95% CI) P β (95% CI) P
Age (per 1 yr) -0.001 (-0.005 to 0.002) 0.437 -0.039 (-0.068 to -0.010) 0.008
Male 0.006 (-0.117 to 0.129) 0.922 0.279 (-0.706 to 1.264) 0.578
Body mass index (per 1 kg/m2) 0.012 (-0.006 to 0.030) 0.180 0.841 (0.720 to 0.961) <0.001
SBP (per 10 mmHg) -0.009 (-0.040 to 0.023) 0.585 0.125 (-0.124 to 0.374) 0.326
DBP (per 10 mmHg) -0.045 (-0.096 to 0.005) 0.077 0.743 (0.349 to 1.138) <0.001
Diabetes mellitus 0.012 (-0.115 to 0.138) 0.856 1.052 (0.041 to 2.062) 0.041
Hypertension 0.096 (-0.026 to 0.219) 0.124 0.294 (-0.695 to 1.283) 0.560
Fasting glucose (per 10 mg/dL) 0.015 (0.001 to 0.029) 0.036 0.011 (-0.101 to 0.124) 0.844
Cholesterol (per 10 mg/dL) -0.016 (-0.029 to -0.003) 0.014 0.185 (0.083 to 0.286) <0.001
Triglyceride (per 1 log)* 0.020 (-0.101 to 0.142) 0.742 3.702 (2.791 to 4.614) <0.001
HDL-C (per 1 mg/dL) -0.006 (-0.011 to -0.001) 0.021 -0.032 (-0.071 to 0.006) 0.099
LDL-C (per 1 mg/dL) -0.001 (-0.002 to 0.001) 0.288 0.011 (-0.001 to 0.023) 0.084
BUN (per 10 mg/dL) 0.063 (-0.004 to 0.130) 0.066 -0.850 (-1.387 to -0.313) 0.002
Creatinine (per 1 mg/dL) 0.089 (0.023 to 0.155) 0.008 -0.477 (-1.009 to 0.054) 0.078
eGFR (per 10 mL/min/1.73 m2) -0.017 (-0.038 to 0.005) 0.132 0.254 (0.081 to 0.427) 0.004
UACR (per 1 log)* 0.084 (0.040 to 0.127) <0.001 -0.221 (-0.585 to 0.142) 0.231
Serum albumin (per 1 g/dL) -0.168 (-0.258 to -0.077) <0.001 2.613 (1.913 to 3.313) <0.001
AST (per 10 U/L) 0.011 (0.003 to 0.020) 0.010 0.022 (-0.049 to 0.092) 0.541
ALT (per 10 U/L) 0.011 (0.002 to 0.020) 0.018 0.091 (0.019 to 0.162) 0.013
Total bilirubin (per 1 mg/dL) 0.223 (0.125 to 0.320) <0.001 -1.033 (-1.828 to -0.238) 0.011
hs-CRP (per 1 log)* 0.177 (0.101 to 0.253) <0.001 -0.485 (-1.073 to 0.104) 0.106
ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; DBP, diastolic blood pressure; eGFR, esti-
mated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein choles-
terol; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio. 
*Log transformed; †per 10 dB/m increase.
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log triglyceride (β = 2.034, P < 0.001), eGFR (β = 0.316, P 
= 0.001), serum albumin (β = 1.386, P < 0.001), ALT (β = 
0.064, P = 0.029), and total bilirubin levels (β = -0.881, P 
= 0.009).
Controlled attenuation parameter is an independent risk 
factor for the presence of metabolic syndrome in patients 
with chronic kidney disease
Logistic regression analysis was performed to investi-
gate the predictive impact of CAP on the prevalence of 
MS in CKD patients (Table 4). CAP was significantly as-
sociated with the prevalence of MS in a crude model (CAP, 
10 dB/m increase; odds ratio [OR], 1.101; 95% confidence 
interval [CI], 1.060-1.143; P < 0.001; data not shown). In 
addition, a significant association remained after adjust-
ment for not only liver function-related factors but also 
traditional risk factors including age, sex, diabetes mel-
litus, hypertension, total bilirubin levels, serum albumin 
levels, eGFR, UACR, hs-CRP, and HDL-C levels (CAP, 10 
dB/m increase; OR, 1.093; 95% CI, 1.009-1.183; P=0.029). 
On the other hand, LS did not show a significant correla-
Table 3. Multiple linear regression analyses for the association of liver stiffness and controlled attenuation parameter with vari-
ables
Variable
Liver stiffness* Controlled attenuation parameter†
β (95% CI) P β (95% CI) P
Age (per 1 yr) 0.023 (-0.007 to 0.052) 0.130
Body mass index (per 1 kg/m2) 0.742 (0.614 to 0.869) <0.001
DBP (per 10 mmHg) 0.041 (-0.295 to 0.378) 0.810
Diabetes mellitus 0.502 (-0.404 to 1.407) 0.277
Fasting glucose (per 10 mg/dL) 0.006 (-0.015 to 0.028) 0.553
Cholesterol (per 10 mg/dL) -0.015 (-0.037 to 0.007) 0.185 0.005 (-0.083 to 0.093) 0.919
Triglyceride (per 1 log)* 2.034 (1.189 to 2.878) <0.001
HDL-C (per 1 mg/dL) -0.005 (-0.014 to 0.005) 0.316
Creatinine (per 1 mg/dL) 0.027 (-0.064 to 0.118) 0.561
eGFR (per 10 mL/min/1.73 m2) 0.316 (0.137 to 0.494) 0.001
UACR (per 1 log)* 0.063 (0.008 to 0.118) 0.026
Serum albumin (per 1 g/dL) -0.115 (-0.287 to 0.056) 0.185 1.386 (0.685 to 2.088) <0.001
AST (per 10 U/L) -0.005 (-0.035 to 0.024) 0.721
ALT (per 10 U/L) 0.007 (-0.019 to 0.032) 0.611 0.064 (0.007 to 0.121) 0.029
Total bilirubin (per 1 mg/dL) 0.309 (0.157 to 0.461) <0.001 -0.881 (-1.536 to -0.226) 0.009
hs-CRP (per 1 log)* 0.030 (-0.104 to 0.165) 0.656
ALT, alanine transaminase; AST, aspartate aminotransferase; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration 
rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio. 
*Log transformed; †per 10 dB/m increase.
Table 4. Controlled attenuation parameter as an independent predictor of metabolic syndrome in patients with chronic kidney 
disease
Model
Liver stiffness, 1 kPa increase CAP, 10 dB/m increase
OR (95% CI) P OR (95% CI) P
Model 1 1.004 (0.982-1.027) 0.696 1.104 (1.062-1.149) <0.001
Model 2 1.003 (0.980-1.026) 0.809 1.132 (1.084-1.182) <0.001
Model 3 0.975 (0.936-1.016) 0.224 1.098 (1.029-1.173) 0.005
Model 4 0.961 (0.910-1.015) 0.155 1.093 (1.009-1.183) 0.029
Model 1: adjusted for age, sex, diabetes mellitus, and hypertension; Model 2: adjusted for Model 1 + total bilirubin and serum albumin; Model 3: adjusted for 
Model 2 + eGFR, UACR, and hs-CRP; Model 4: adjusted for Model 3 + HDL-C.
CAP, controlled attenuation parameter; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-
CRP, high sensitivity C-reactive protein; OR, odds ratio; UACR, urine albumin-to-creatinine ratio. 
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tion with the presence of MS in CKD patients. The asso-
ciation between CAP groups which were divided into five 
groups, and full-adjusted odds ratio was constructed and 
described as cubic spline curves in Fig. 2. As shown, the 
OR is increased from around 3rd group, then the statisti-
cal significance is appears around 4th group. In addition, 
the mean value of CAP linearly increased with the num-
ber of MS components, and the trend showed significant 
statistic power (P for trend < 0.001, Fig. 3).
Body mass index and triglyceride levels are the main 
factors affecting the predictive role of controlled 
attenuation parameter in diagnosing metabolic syndrome
To investigate the main factors affecting the predictive 
power of CAP in diagnosing MS, the proportion of diag-
nosed MS components according to the dichotomized 
CAP is presented (Fig. 4). High and low CAP groups were 
generated by the median value of CAP score. Among the 
five diagnostic criteria of MS, BMI (27.7% vs. 72.3%, P < 
0.001) and triglyceride levels (32.5% vs. 67.5%, P < 0.001) 
were significantly more prevalent in the higher-CAP 
compared with the lower-CAP group, but fasting plasma 
glucose levels, HDL-C levels, and systolic blood pressure 
were not significantly different between groups.
Discussion
In the present study, we found that the CAP value was 
independently associated with the presence of MS in pre-
dialysis CKD patients. The liver and muscles are target 
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Figure 2. A cubic spline curves for the presence of metabolic 
syndrome according to the degree of CAP values in patients 
with chronic kidney disease. The models were adjusted for age, 
gender, history of diabetes mellitus and hypertension, total bilirubin, 
serum albumin, eGFR, UACR, hs-CRP, and HDL-C. The solid line repre-
sents the log odds of metabolic syndrome according to CAP, and the 
dotted line representes 95% CI.
CAP, controlled attenuation parameter; CI, confidence interval; eGFR, 
estimated glomerular filtration rate; HDL-C, high-density lipoprotein 
cholesterol; hs-CRP, high sensitivity C-reactive protein; UACR, urine 
albumin-to-creatinine ratio.
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Figure 3. Controlled attenuation parameter according to the 
number of metabolic syndrome (MS) components. Each bar 
represents the mean and 95% confidence interval. Controlled at-
tenuation parameter values increased in parallel with the number of 
metabolic syndrome components (P < 0.001). 
CAP, controlled attenuation parameter.
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Figure 4. The proportions of metabolic factors which satisfy 
the criteria of metabolic syndrome (MS) according to the di-
chotomized CAP. Among the five diagnostic criteria of MS, BMI 
(27.7% vs. 72.3%, P < 0.001) and TG (32.5% vs. 67.5%, P < 0.001) 
showed significant higher proportions in the higher CAP group than 
the lower CAP group, but fasting plasma glucose, HDL-C, and SBP 
did not show differences between the two groups. 
BMI, body mass index; CAP, controlled attenuation parameter; HDL-
C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; 
TG, triglyceride. 
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organs for insulin action. Recently, the role of the liver in 
insulin resistance is being investigated; several observa-
tional studies suggest that NAFLD is closely associated 
with insulin resistance and sarcopenia [23]. Hitherto, 
the underlying mechanisms for an association between 
NAFLD and sarcopenia are not fully elucidated. Previous 
studies proposed that hepatic steatosis was strongly cor-
related with insulin resistance, mitochondrial dysfunc-
tion, and consequent muscle breakdown [24]. In particu-
lar, several adipokines produced by adipose tissues are 
reported to be involved in modulating insulin action in 
metabolic tissues such as the muscles and liver [25]. Fur-
thermore, patients with chronic liver disease or cirrhosis 
reportedly have lower levels of insulin growth factor-1 
and increased levels of various cytokines such as tumor 
necrosis factor alpha and transforming growth factor 
beta, which are significantly associated with sarcopenia 
[26]. In a previous study, sarcopenia was commonly re-
ported in CKD patients and was related to protein-energy 
wasting, inflammation, and cardiovascular mortality in 
them [6,27]. In our study, CAP values as a marker for he-
patic steatosis were significantly higher in CKD patients 
with MS in accordance with previous studies performed 
on patients without kidney abnormalities.
Studies on the association between obesity and meta-
bolic risk factors have shown conflicting results in CKD 
patients. Although an inverse association between BMI 
and survival rates is reported in CKD patients including 
dialysis patients [28,29], several studies show that central 
obesity assessed through anthropometric measurements 
is associated with a higher risk of cardiovascular mortal-
ity in patients with CKD as well as dialysis patients [30]. 
These data suggested that metabolic abnormalities af-
fected by visceral adiposity might be an important risk 
factor for cardiovascular mortality and morbidity. Ac-
cumulation of visceral fat leads to increased excretion of 
pro-inflammatory cytokines that may stimulate aggrava-
tion of hepatic steatosis and have a catabolic effect on 
the skeletal muscles [31]. Since CKD leads to metabolic 
abnormalities such as impaired glucose and protein 
metabolism, increased oxidative stress, and systemic in-
flammation, MS in CKD patients is frequently observed 
and is also considered a non-traditional risk factor for 
cardiovascular outcomes. The present study suggested 
that measurement of hepatic steatosis could help to de-
tect MS in CKD patients.
Transient elastography is a newly invented diagnostic 
tool that is non-invasive, painless, easy to perform, and 
has superior reliability for pathologic diagnosis [32]. Be-
cause of the unique role of the liver in the regulation of 
metabolic derangement, the use of transient elastogra-
phy has been expanded  to evaluate NAFLD and MS [9]. 
CAP is calculated by using the velocity and intensity of 
reflected ultrasonic signals; it reveals the stiffness, viscos-
ity, and elasticity of the liver; thus, CAP could measure 
hepatic steatosis.
The CAP score, distinct from the LS score obtained 
through transient elastography, has been recently estab-
lished and determined as a reliable method to detect he-
patic steatosis [13,14,22]. In addition, a large prospective 
study revealed that CAP was significantly correlated with 
traditional metabolic risk factors such as age, sex, and 
BMI as well as MS itself [14]. One previous study already 
revealed the usefulness of CAP in CKD patients, showing 
that hepatic steatosis measured with CAP was signifi-
cantly correlated with serum creatinine and hs-CRP lev-
els [33]. The present study also demonstrated that LS was 
closely correlated with liver function parameters such 
as serum albumin and prothrombin time [12]. CAP was 
significantly increased in CKD patients with MS, and CAP 
was independently associated with BMI and triglyceride 
levels in multiple linear regression analysis. In addition, 
increased CAP was independently associated with the 
presence of MS in the CKD population after adjustment 
for multiple factors, including liver function-related and 
traditional risk factors. Further analysis indicated that 
the significant association between CAP and MS in CKD 
patients is mainly caused by BMI and serum triglyceride 
levels. Obesity is the most significant single risk factor 
for the development of hepatic steatosis [34], especially 
excess central or visceral fat [35]. Based on these obser-
vations, CAP using transient elastography can be a useful 
tool to detect MS and central obesity in CKD patients, 
consistent with previous studies.
Our study has several limitations. First, the assess-
ment of MS was made only at a single time point, and the 
present study was performed by using a cross-sectional 
analysis method. For clarifying the clinical impact of CAP 
on patients with renal impairment, prospective follow-
up studies are necessary. Second, the study patients were 
relatively skewed to stage 1 or 2 CKD; thus, the applica-
tion of this result to patients with moderate to severe 
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CKD is limited. Finally, since we did not measure muscle 
strength or skeletal mass, the association between MS 
and sarcopenic obesity is unclear. Further confirmatory 
studies to examine the possible mechanisms of the effect 
of hepatic steatosis on muscle mass and MS development 
are warranted.
In conclusion, increased CAP measured with transient 
elastography was significantly associated with an in-
creased risk of MS in CKD patients. These data suggest 
that hepatic steatosis measured with CAP could be a 
novel surrogate marker for MS in CKD patients.
Conflicts of interest
All authors have no conflicts of interest to declare. 
Acknowledgments
We thank the Institute of Gastroenterology, Yonsei Uni-
versity College of Medicine for providing data about tran-
sient elastography. This work was supported by the Brain 
Korea 21 Project for Medical Science, Yonsei University, 
by the National Research Foundation of Korea (NRF) 
grant funded by the Korea government (MEST) (No. 
2014–050098), and by a grant of the Korea Healthcare 
Technology R&D Project, Ministry of Health and Welfare, 
Republic of Korea (H14C2003).
References
[1] Grundy SM: Obesity, metabolic syndrome, and cardiovas-
cular disease. J Clin Endocrinol Metab 89:2595-2600, 2004 
[2] Kurella M, Lo JC, Chertow GM: Metabolic syndrome and 
the risk for chronic kidney disease among nondiabetic 
adults. J Am Soc Nephrol 16:2134-2140, 2005
[3] Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, 
Kinjo K, Takishita S, Iseki K: Metabolic syndrome and risk 
of developing chronic kidney disease in Japanese adults. 
Hypertens Res 30:937-943, 2007
[4] Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, 
Taskinen MR, Groop L: Cardiovascular morbidity and mor-
tality associated with the metabolic syndrome. Diabetes 
Care 24:683-689, 2001
[5] Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: 
Reverse epidemiology of cardiovascular risk factors in 
maintenance dialysis patients. Kidney Int 63:793-808, 2003
[6] Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman 
ME, Barany P, Stenvinkel P, Lindholm B: Obese sarcope-
nia in patients with end-stage renal disease is associated 
with inflammation and increased mortality. Am J Clin Nutr 
86:633-638, 2007
[7] Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, 
Levey AS, Sarnak MJ: Waist-to-hip ratio and body mass 
index as risk factors for cardiovascular events in CKD. Am J 
Kidney Dis 52:49-57, 2008
[8] Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi 
M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Toda H, Na-
kamura N, Fukui M: Metabolically healthy obesity and risk 
of incident CKD. Clin J Am Soc Nephrol 10:578-583, 2015
[9] Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Con-
treras M, Landt CL, Harrison SA: Prevalence of nonalco-
holic fatty liver disease and nonalcoholic steatohepatitis 
among a largely middle-aged population utilizing ultra-
sound and liver biopsy: a prospective study. Gastroenterol-
ogy 140:124-131, 2011
[10] Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, 
Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: 
Nonalcoholic fatty liver disease: a feature of the metabolic 
syndrome. Diabetes 50:1844-1850, 2001
[11] Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, 
Bellentani S: Prevalence of and risk factors for nonalcoholic 
fatty liver disease: the Dionysos nutrition and liver study. 
Hepatology 42:44-52, 2005
[12] Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, 
Adhoute X, Bertet J, Couzigou P, de Lédinghen V: Diagnosis 
of cirrhosis by transient elastography (FibroScan): a pro-
spective study. Gut 55:403-408, 2006
[13] Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, Ahn 
SH, Chon CY, Lee HW, Park Y, Han KH: Controlled attenu-
ation parameter (CAP) for detection of hepatic steatosis in 
patients with chronic liver diseases: a prospective study of 
a native Korean population. Liver Int 34:102-109, 2014
[14] de Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiri-
art JB, Cassinotto C, Merrouche W, Foucher J, Brigitte le B: 
Controlled attenuation parameter (CAP) for the diagnosis 
of steatosis: a prospective study of 5323 examinations. J 
Hepatol 60:1026-1031, 2014
[15] American Diabetes Association: Diagnosis and classifica-
tion of diabetes mellitus. Diabetes Care 37 Suppl 1:S81-S90, 
2014
[16] James PA, Oparil S, Carter BL, Cushman WC, Dennison-
Himmelfarb C, Handler J, Lackland DT, LeFevre ML, Mac-
Yoon, et al. Fatty liver in chronic kidney disease
57www.krcp-ksn.org
Kenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler 
SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E: 2014 
evidence-based guideline for the management of high 
blood pressure in adults: report from the panel members 
appointed to the Eighth Joint National Committee (JNC 8). 
JAMA 311:507-520, 2014
[17] Stevens PE, Levin A: Evaluation and management of chron-
ic kidney disease: synopsis of the kidney disease: improv-
ing global outcomes 2012 clinical practice guideline. Ann 
Intern Med 158:825-830, 2013
[18] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 
3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, 
Coresh J: A new equation to estimate glomerular filtration 
rate. Ann Intern Med 150:604-612, 2009
[19] Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults: Executive summary 
of the third report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). JAMA 285:2486-2497, 2001
[20] Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, 
Shimono K, Yamane Y: The new BMI criteria for asians by 
the regional office for the western pacific region of WHO 
are suitable for screening of overweight to prevent meta-
bolic syndrome in elder Japanese workers. J Occup Health 
45:335-343, 2003
[21] Shiwaku K, Nogi A, Kitajima K, Anuurad E, Enkhmaa B, Ya-
masaki M, Kim JM, Kim IS, Lee SK, Oyunsuren T, Yamane Y: 
Prevalence of the metabolic syndrome using the modified 
ATP III definitions for workers in Japan, Korea and Mongo-
lia. J Occup Health 47:126-135, 2005
[22] Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcel-
lin P, Poupon R, Sandrin L, Miette V: Controlled attenu-
ation parameter (CAP): a novel VCTE™ guided ultrasonic 
attenuation measurement for the evaluation of hepatic 
steatosis: preliminary study and validation in a cohort of 
patients with chronic liver disease from various causes. Ul-
trasound Med Biol 36:1825-1835, 2010
[23] Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim 
NH, Baik SH, Choi DS, Choi KM: Relationship between 
sarcopenia and nonalcoholic fatty liver disease: the Korean 
Sarcopenic Obesity Study. Hepatology 59:1772-1778, 2014  
[24] Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang 
ES, Han KH, Lee HC, Cha BS: Sarcopaenia is associated 
with NAFLD independently of obesity and insulin resis-
tance: Nationwide surveys (KNHANES 2008-2011). J Hepa-
tol 63:486-493, 2015
[25] Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte 
biology. Adipose tissue function and plasticity orchestrate 
nutritional adaptation. J Lipid Res 48:1253-1262, 2007
[26] Tessari P: Protein metabolism in liver cirrhosis: from albu-
min to muscle myofibrils. Curr Opin Clin Nutr Metab Care 
6:79-85, 2003
[27] Kara E, Sahutoglu T, Ahbap E, Sakaci T, Koc Y, Basturk T, 
Sevinc M, Akgol C, Unsal A: The predictive value of malnu-
trition - inflammation score on 1-year mortality in Turkish 
maintenance hemodialysis patients. Clin Nephrol 86:94-99, 
2016
[28] Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, 
Shinaberger CS, Gjertson DW, Greenland S: Association of 
morbid obesity and weight change over time with cardio-
vascular survival in hemodialysis population. Am J Kidney 
Dis 46:489-500, 2005
[29] Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, 
Young EW: Body mass index and mortality in ‘healthier’ 
as compared with ‘sicker’ haemodialysis patients: results 
from the Dialysis Outcomes and Practice Patterns Study 
(DOPPS). Nephrol Dial Transplant 16:2386-2394, 2001
[30] Beyer I, Mets T, Bautmans I: Chronic low-grade inflam-
mation and age-related sarcopenia. Curr Opin Clin Nutr 
Metab Care 15:12-22, 2012
[31] Kalyani RR, Corriere M, Ferrucci L: Age-related and dis-
ease-related muscle loss: the effect of diabetes, obesity, 
and other diseases. Lancet Diabetes Endocrinol 2:819-829, 
2014
[32] Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida 
H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Ko-
bayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito 
S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo 
S, Nakajima A: Noninvasive assessment of liver fibrosis by 
measurement of stiffness in patients with nonalcoholic 
fatty liver disease (NAFLD). Dig Liver Dis 40:371-378, 2008
[33] Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L: 
Chronic kidney disease and nonalcoholic fatty liver disease 
proven by transient elastography. Kidney Blood Press Res 
37:305-310, 2013
[34] James O, Day C: Non-alcoholic steatohepatitis: another 
disease of affluence. Lancet 353:1634-1636, 1999
[35] Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De 
Moura MC: Non-alcoholic fatty liver: another feature of the 
metabolic syndrome? Clin Nutr 18:353-358, 1999
